Kliogest

Norethisterone acetate and estradiol, the active ingredients in Kliogest, constitute a combined estrogen‑progestogen oral contraceptive presented as a tablet for oral use. It is indicated for contraception in women of reproductive age by suppressing ovulation and inducing cervical mucus and endometrial changes that prevent implantation.

GNH USA supplies Kliogest as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product quality through rigorous testing and maintains appropriate handling for stability, though the tablet is stored at ambient temperature.

Kliogest, a combined estrogen‑progestogen oral contraceptive, is used for hormonal contraception.

Contraception: prevents pregnancy by inhibiting ovulation and altering cervical mucus and endometrial lining. Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns. Reduction of menstrual-associated symptoms: may lessen dysmenorrhea and premenstrual discomfort.

Kliogest may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort. - Spotting or irregular bleeding: breakthrough bleeding between periods. - Mood changes: irritability or mild depressive symptoms. - Weight gain: modest increase in body weight.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in deep veins. - Pulmonary embolism: clot traveling to lungs. - Stroke: cerebrovascular accident. - Myocardial infarction: heart attack. - Severe hypertension: markedly elevated blood pressure. - Liver dysfunction: jaundice or abnormal liver enzymes. - Allergic reactions: rash, swelling, or anaphylaxis.

Before prescribing Kliogest, clinicians should consider several safety measures.

Assess cardiovascular risk: evaluate history of thrombosis before prescribing. Screen for contraindications: avoid in smokers over 35 and in women with estrogen‑dependent tumors. Monitor blood pressure: check regularly during therapy. Consider drug interactions: avoid concomitant use of strong enzyme inducers that may reduce efficacy. Store at ambient temperature: keep tablets in original packaging, protect from moisture and light.

Kliogest can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive efficacy. - Selective estrogen receptor modulators (e.g., tamoxifen): may antagonize contraceptive effect. - Anticoagulants (e.g., warfarin): may increase bleeding risk.

Moderate Interactions (Monitor Closely): - Antiepileptics (e.g., phenytoin): may lower hormone levels. - Antidepressants (SSRIs): may increase side‑effect profile. - Certain antibiotics (e.g., tetracycline): generally minimal effect but monitor breakthrough bleeding.